MapLight Therapeutics (MPLT) Long-Term Investments (2024 - 2025)
MapLight Therapeutics recorded quarterly Long-Term Investments of $148.0 million in Q4 2025, up 1200.47% quarter-over-quarter from $11.4 million in Q4 2024, and up 1200.47% year-over-year from $11.4 million in Q4 2024.
MapLight Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $148.0 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 1200.47% year-over-year to $148.0 million; the TTM figure through Dec 2025 stood at $148.0 million (up 1200.47% YoY), while the FY2025 annual figure was $148.0 million, up 1200.47% from the prior year.
- Long-Term Investments came in at $148.0 million for Q4 2025 at MapLight Therapeutics, up from $11.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $148.0 million in Q4 2025 to a low of $11.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 147.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147.99 Mn |
| Dec 31, 2024 | 11.38 Mn |